Johnson & Johnson invests over $1 billion in a new Pennsylvania cell therapy manufacturing facility for cancer and neurological diseases. The expansion addresses growing demand for advanced therapies while highlighting workforce training challenges in GMP environments. Other developments include new cell line technology for viral vector production and CRISPR-edited CAR-T manufacturing partnerships.
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Johnson & Johnson announced a $1 billion cell therapy manufacturing facility in Pennsylvania while reportedly exploring a sale of its DePuy Synthes orthopedics business for over $20 billion.
The global drug discovery services market is valued at $22.04 billion in 2025 and is forecast to reach $75.13 billion by 2034, growing at a 14.6% CAGR from 2026-2034, driven by rising industry demand and technological advancements.
Johnson & Johnson announced a more than $1 billion investment to build a new cell therapy manufacturing facility in Lower Gwynedd, Pennsylvania, creating 500 skilled biomanufacturing jobs and 4,000 construction jobs as part of its $55 billion U.S. investment strategy through early 2029.
Johnson & Johnson announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, expected to create 500 jobs when fully operational in 2031.
Johnson & Johnson announced plans to invest over $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, creating 500 biomanufacturing jobs as part of its $55 billion U.S. expansion commitment through 2029.
Johnson & Johnson announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, part of the company's $55 billion U.S. investment strategy through early 2029.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07456358 |
Autoimmune Neurological Diseases and Those Secondary to Immunotherapy: Study of Immunological Mechanisms and Research Into Targets of Immune Attack |
NOT_YET_RECRUITING | NA |
| NCT06537791 |
Impact of Home-Based Rehabilitation on Motor Function and Mood in Individuals With Disabilities |
COMPLETED | NA |
| NCT05515419 |
Allogeneic Cord Blood for Neurological Diseases in Adults |
WITHDRAWN | EARLY_PHASE1 |
| NCT05486052 |
Rehabilitation With Biofeedback in Neurology |
COMPLETED | NA |
| NCT04995848 |
Telepalliation - Digital Platform for Patients in Palliation and Their Relatives |
UNKNOWN | NA |
| NCT04846764 |
Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM) |
UNKNOWN | NA |
| NCT02790424 |
Adjustment Exploratory Protocols and Functional Evaluation of New Non Invasive Devices in Patient Volunteers |
COMPLETED | NA |
| NCT02455284 |
In Vivo and ex Vivo Validation of MR Tractography of Brain White Matter Tracts - FIBRATLAS II-III |
COMPLETED | NA |
| NCT02340871 |
Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases |
UNKNOWN | |
| NCT02018406 |
Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury |
RECRUITING | PHASE1/PHASE2 |
